At the forefront of the SBF 120, Exosens shares climb 2.5% ahead of results
The Bordeaux-based optoelectronics company is recovering mid-morning in a rising Paris market. After a decline in the previous session, the stock regains ground and extends a consolidation momentum following recent turbulence.
A rebound that places Exosens among the top gainers of the SBF 120
The stock gains 2.37% to €58.35, versus €57 at the previous close, and ranks among the strongest increases in the SBF 120, which advances 0.58%. The move follows a decline in the previous session, during which the value had already fallen after its rebound linked to American neutron detectors. Over one week, the gain stands at 3%, and reaches 21.56% over one year. On the eve of this session, the CAC 40 was also up 0.57%, while the Dow Jones and S&P 500 had slightly declined on Wall Street Tuesday.
The stock remains below its three moving averages, from MA20 to MA200
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Despite this rebound, the price remains below the MA20 at €59.18 (gap of 1.40%), the MA50 at €59.75 and the MA200 at €60.09, the furthest, at 2.90%. The MACD, at -0.49 versus -0.20 for its signal line, confirms a momentum still oriented downward, while the RSI at 45 remains neutral. The support at €54.15 remains approximately 7% below the current price, while resistance at €63.40 is located approximately 9% above. Reclaiming €59 to €60 would constitute the first test for the stock, before the publication of nine-month results, expected on October 27.
Porté par une dynamique commerciale soutenue, en particulier sur les marchés de la Défense et de la Surveillance, ainsi que par une solide exécution opérationnelle
Risks mentioned
Charge de dépréciation de la marque de 28,2 M€ pesant sur le résultat net publié, en baisse de 45,0 %
Incertitudes persistantes sur la recherche scientifique pesant sur la demande en Sciences de la Vie
Contraction de 60 points de base de la marge brute du segment Détection & Imagerie (mix produits)
Opportunities identified
Attribution par l'US Army du contrat IDIQ BiNOD ouvrant le marché américain de la défense
Plan d'expansion de +40 % des capacités de production d'ici 2027, premiers bénéfices au S2 2026
Acquisition d'Emberion, capteurs infrarouges SWIR à points quantiques
Outlook / guidance
Expected revenue: 530 millions d'euros
Expected EBITDA: 173 millions d'euros
Management commentary: chiffre d'affaires compris entre 520 millions d'euros et 540 millions d'euros ; • EBITDA ajusté compris entre 168 millions d'euros et 178 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
